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Background: The pathophysiology of type2 diabetes differs between different ethnic groups. Asians develop type2
diabetes at younger age, lower body mass index, and in relatively short time. Not only that, some ethnicities have
different responses and dosing regimens to different classes of anti-diabetic agents. Data from Japanese population
showed that the optimal doses of liraglutide used are smaller than other population and that weight loss is not as
effective as seen in Caucasians.
Methods: We aimed to assess liraglutide efficacy in reducing weight and HbA1c in Arab population when used as
add on to other anti-diabetic agents. We prospectively followed patients who were recruited to treatment with
liraglutide for a 6 months period; at the start of the study we checked patients’ demographics, weight, blood
pressure, fasting blood glucose, HbA1c, lipid panel, LFTs and creatinine. Patients were checked at 3 months and at
the end of the study at 6 months.
Results: There was a significant reduction in weight at 3 and 6 months from a mean weight of 96.01 ± 19.2 kg to
(94.8 ± 20 kg with (P < 0.001)) and 94.5 ± 19 kg with (p < 0.001) respectively. Mean HbA1c at baseline was 8.3 ± 1.7 %
dropped to 7.7 ± 1.4 % (p < 0.001) at 3 months, and 7.6 + 1.6 % (p < 0.001) at 6 months.
Conclusions: Liraglutide is effective in reducing weight, HbA1c as well as other metabolic parameters in Arab
population with type2 diabetes.
Trial registration: The trial is approved and registered with the Institutional Ethical Committee Board (Dubai Health
Authority Medical Research Committee) under registration Number (MRC-08/2013_03).
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In healthy individuals the delicate balance between beta
and alpha cells maintains the normal glucose homeosta-
sis; elevated blood glucose results in inhibition of alpha
cell production of glucagon and stimulation of beta cell
production of insulin. This balance is disturbed in pa-
tients with diabetes, resulting in loss of first phase insu-
lin response and increased glucagon levels [1, 2].
GLP-1 is a hormone produced in the gastrointestinal
tract in response to oral meal; it stimulates insulin secre-
tion, and inhibits glucagon production both in a glucose* Correspondence: Alaaeldin11@gmail.com
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medium, provided the original work is prope
creativecommons.org/publicdomain/zero/1.0dependent manner. It also delays gastric emptying, and
promotes satiety and hence results in improved post-
prandial glycaemic control [3]. Liraglutide is a GLP-1
analogue that has 97 % structural homology to native
GLP-1 and is used in the treatment of type2 diabetes as
it has proved effectiveness in all LEAD trials (monother-
apy or combination therapy) in reducing HbA1c and
weight in all patients regardless of their ethnicity, weight
and sex [3].
The pathophysiology of type2 diabetes differs between
ethnic groups leading to a diverse clinical presentation.
Asians develop diabetes in a relatively short time, in
younger population, and with lower body mass index
compared to other ethnic groups [4]. Many studies haverticle distributed under the terms of the Creative Commons Attribution License
, which permits unrestricted use, distribution, and reproduction in any
rly credited. The Creative Commons Public Domain Dedication waiver (http://
/) applies to the data made available in this article, unless otherwise stated.
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have suggested that impaired insulin secretion as the
main defect based on the fact that the insulin secreting
capacity in Japanese is only 50 % of that observed in
Caucasians [5, 6]. Other studies found a more pro-
nounced incretin defect in Asians than in Caucasians
[5]. The DECODE-DECODA study showed that the
pathophysiologic defect in Caucasians is mainly a higher
insulin resistance [6].
These differences in pathophysiology might explain
different responses to some anti-diabetic medications. In
one study that assessed glucagon response to liraglutide
injection showed that it did not cause significant reduc-
tions in fasting or post prandial glucagon levels in Japanese
type2 diabetics. This finding was attributed to the alpha
cell characteristic of being affected by heterogeneity of the
pathogenesis of diabetes, although the smaller dose used
for Japanese population could be a contributing factor [3].
There were very little in literature to evaluate the
effect of liraglutide in different ethnic groups; studies in
Japanese population showed that liraglutide as mono-
therapy results in −2.34 kg weight reduction [7], but are
weight neutral when used in combination with other
oral anti-diabetic agents [4, 8]. Furthermore smaller
doses of liraglutide (0.1–0.3 mg qd) did not result in im-
provement in HOMA-IR and HOMA-B, while higher
doses (0.6 0.9 mg qd) resulted in (−0.32 and −0.53) re-
duction in HOMA-IR and increased HOMA-B (22 and
21.05 respectively) [7]. Another two studies have shown
that liraglutide has a superior effect in reducing HbA1c
in Asian population than in Caucasians.
The prevalence of diabetes and obesity is very high in
the Arab countries, and according to last IDF (Inter-
national Diabetes Federation) data the prevalence in
United Arab Emirates is as high as 19 %. Unfortunately
there are no enough data on the efficacy of this new
class in Arab population, neither on the pattern of pre-
scription. Our search for studies that evaluated the effi-
cacy of these therapies in Arab population has revealed
only one study. In this study the authors retrospectively
assessed the effect of Sitagliptin in 53 UAE nationals
and concluded that sitagliptin results in modest but
important reductions in HbA1c and is associated with
minimal side effects [9]. In this trial we aimed to
evaluate the effect of Liraglutide in reducing HbA1c
and weight on Arab population.Patients and methods
Aim of the study
We aim to evaluate the efficacy of liraglutide as add on
therapy to other anti-diabetic agents in reducing
HbA1c and weight in Arab population with type2
diabetes.Primary end point
The primary end point of the study is to assess the
change in weight and HbA1c from base line at 6 months.
Secondary end point
We plan to assess the changes in lipid panel (total
cholesterol and triglycerides), BP, creatinine from base-
line and at 6 months.
Study design
This prospective observational study was conducted at
Dubai Hospital and two other centres in Dubai Health
Authority, in the United Arab Emirates. The aim of this
study was to assess the efficacy of liraglutide in reducing
HbA1c and weight in Arabs with type2 diabetes. The
study adhered to the tenets of the Declaration of
Helsinki. The protocol was compliant with the Health
Insurance Portability and Accountability Act and has
been approved by the institutional review board and was
given a reference number (MRC-08/2013_03). As per
local recommendations, consent for participation in the
study was obtained from all participants in the trial.
The primary end point of the study was the mean
change in HbA1c and in weight from baseline and after
6 months of treatment. The changes in lipid panel from
baseline to the end of follow-up were analysed as sec-
ondary end points, as were blood pressure (BP) and
creatinine changes.
Patient recruitment
All adult patients with type2 diabetes aged between 18
and 70 years, who were started on liraglutide in the
period from January 2014 to March 2014 were recruited
to the study. The prescription of liraglutide was compliant
with the local recommendations; hence patients with
type1 diabetes, severe renal impairment, pregnant women,
and those with history of pancreatitis were not prescribed
liraglutide. We also excluded non-Arab patients, and
those who did not complete the period of six months on
therapy. The dose of liraglutide started at 0.6 mg once per
day subcutaneously and increased after one week to
1.2 mg and after another week to 1.8 mg per day. Those
who did not tolerate the 1.2 mg were excluded from the
study, while those who did not tolerate the 1.8 mg were
advised to continue with 1.2 mg per day (1.2–1.8 mg were
the doses used in LEAD trials).
After collecting informed consent, patients’ demo-
graphics (age, sex, and ethnic group), co-morbidities,
concurrent medications, weight, blood pressure were
recorded. Laboratory tests included fasting blood glucose,
HbA1c, creatinine, lipid profile (Total cholesterol, Low-
density lipoprotein, Triglycerides). Patients were then ad-
vised to attend for two visits in 3 months in which weight
and HbA1c were collected. At 6 months (end of study visit)
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AST and ALT were recorded. Changes in pharmacologic
therapy for hypertension and dyslipidaemia were allowed if
it was deemed necessary and was left to the discretion of
the treating physician.
Definitions
Patients were considered to have type2 diabetes if they
fulfilled the ADA (American Diabetes Association) cri-
teria for diagnosis of diabetes mellitus (FBG ≥126 mg/dl,
RBG ≥200 mg/dl, or HbA1c ≥6.5 %) [10], or if they are
already on anti-diabetic agents. Patients on metformin
alone are not considered diabetic unless they fulfil the
ADA (American Diabetes Association) criteria as many
young ladies were on metformin for treatment of other
medical problems e.g. polycystic ovarian syndrome. Hyper-
tension was defined as a systolic blood pressure ≥140 mmHg
and/or diastolic blood pressure ≥90 mmHg or being on anti-
hypertensive medications.
Data analysis
The population of our study included Arabs with type2
Diabetes mellitus who are obese or overweight. The
sample size was calculated as 380 patients to provide a
power of 95 % to detect the effects of liraglutide on
weight and HbA1c.
Data analysis was performed on SPSS software 16.0. In
all analysis, a p-value <0.05 was considered significant
and P < 0.001 considered highly significant.
Quantitative variables were described as mean; SD and
range, qualitative were described as variables as number
and percentage. We have used the Chi-square test to
compare qualitative variables between groups. The un-
paired t-test was used to compare quantitative variables,
in parametric data (SD < 50 % mean), while the Mann
Whitney test was used instead of unpaired t-test in non-
parametric data.
We used the Paired t-test to compare quantitative
variable within the same group before and after in para-
metric data (SD < 50%mean), and the Willcoxon test was
used instead of paired t-test in non-parametric data
(SD > 50%mean).
Results
Total number of patients screened was 463 patients; only
365 were recruited to the study and signed informed con-
sent. The main reason for exclusion was patient’s unwill-
ingness to sign an informed consent; furthermore, some
patients were excluded, as they were lost to follow-up.
Twelve patients stopped liraglutide in less than 2 months
due to gastrointestinal side effects (3 patients did not toler-
ate increasing the dose of liraglutide from 1.2 to 1.8 mg
and were allowed to continue the study); and another 3
developed skin rash following administration of liraglutide.The rash was macular in one patient and the other 2
developed wheals (urticaria) at the site of injection
that disappeared within 48 h after stopping the injec-
tion. The rash recurred even after changing the needle
and the pen. Five patients did not start the treatment
or used only one or two doses after prescription be-
cause of needle phobia. Thirteen patients underwent
bariatric surgery and had liraglutide discontinued post
operatively. Fifteen patients failed to provide blood
samples despite attending the clinics for re-fill pre-
scription, 10 patients were lost to follow up, and fi-
nally 10 patients withdrew their consent (Fig. 1).
Out of the 365 patients included in the final
analysis, 29 % were males (n = 106), and 71 % were fe-
males (n = 259). The mean age was 50.4 ± 10 years.
Base line characteristics of participants are shown in
(Table 1). At base line 56.34 % of patients were on in-
sulin based regimen either basal-plus, basal bolus, or
premixed. 90.1 % of patients were on metformin,
43.5 % were on sulphonyureas, 10.7 % were on DPP4
inhibitors, 0.8 % on Acarbose, and 85.2 % were on
statins.
At base line the mean weight was 96.01 ± 19.2 kg;
after 3 months of starting liraglutide the mean weight
reduction was highly significant; 94.8 ± 20 kg with (p <
0.001)) and a percentage change of 2.01 ± 0.3 kg. At
6 months the mean weight was 94.5 ± 19 kg with (p <
0.001) and percentage change of 2.5 ± 0.6 kg; this was
again highly significant. The change in weight was sig-
nificant even when data was adjusted for age, gender,
medications, and co-morbidities (Fig. 2).
Change in HbA1c was highly significant, with a change
from baseline of 8.3 ± 1.7 to 7.7 ± 1.4 % (p < 0.001), and
7.6 + 1.6 % (p < 0.001) at 3 and 6 months respectively.
Change in HbA1c was highly significant even after cor-
rection for age, gender, medications and co-morbidities
(Fig. 3).
There was a highly significant change in the total
cholesterol level 6 months after starting treatment
with liraglutide; the total cholesterol level has changed
from 165.2 ± 40 mg/dl at baseline to 153.6 ± 35 mg/dl
(p < 0.001) at 6 months. The same findings were seen
with triglyceride, which has changed from 142.3 ±
68 mg/dl at baseline to 131.4 ± 61 mg/dl (p < 0.001) at
6 months (Fig. 4).
There was no significant change in systolic blood
pressure at the end of the study. The diastolic blood
pressure has dropped on therapy from a mean of
74.4 ± 10 mmHg at baseline to 72 ± 9 mmHg at
6 months, this was highly significant with p < 0.001.
Serum creatinine has changes from 0.77 ± 0.19 mg/dl
at base line to 0.76 ± 0.2 mg/dl at the end of the
study. This change was not statistically significant.
The P value was = 0.10.
Fig. 1 Screening, recruitment and reasons for exclusion from final analysis
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Liraglutide is a GLP1 analogue that has proved very
effective in reducing HbA1c not only as monotherapy as
in LEAD 3 trial, but also in combination with oral
hypoglycaemic agents as in LEAD 2 and LEAD 3. In all
of these trials it resulted in 1.2–1.6 % reduction in
HbA1c at doses of 1.2–1.8 mg. In LEAD 5 the percent-
age of patients achieving HbA1c <7 % and <6.5 % was
higher when compared to those on metformin glimepir-
ide and glargine [11].
In the Japanese population liraglutide was found to re-
sult in increased insulin secretion, suppression of gluca-
gon, decreased glucose variability and a significantly
reduced HbA1c, despite using a smaller dose (0.9 mg)
[3]. Liraglutide when used as monotherapy compared to
glimepiride in Japanese population resulting in superior
HbA1c and weight reduction and was well tolerated
[12]. Moreover it was found that the use of liraglutide
resulted in a meaningful long-term weight loss and sig-
nificantly improved eating behavior in obese Japanese
patients with type2 diabetes [13]. In agreement with all
previous trials, the use of liraglutide in our cohort (Arab
population) has resulted in a significant reduction in
HbA1c that ranged from 0.5 to 1.15 % in HbA1c in
6 months of therapy. These findings indicate thatliraglutide is efficacious in lowering A1c and weight in
Arab population and seems to have similar results to
other trials in different races.
In their meta-analysis on the incretin based therapies
in type2 Asian population, Melva et al. have concluded
that out of all GLP-1 analogues exenatide was the only
drug that resulted in significant weight loss in Asian
population while liraglutide was weight neutral [14],
these results were similar to data shown by Kendall et al.
[15]. In the LEAD program the weight loss has ranged
between 1.8 and 3.2 kg, depending on the dose of lira-
glutide and the combination therapy used in the pro-
gram [11]. In our Cohort weight loss, it ranged between
0.5 and 17 kg with a mean weight loss of 2.5 ± 0.6 kg.
Obesity can result in many adverse cardiovascular out-
comes including heart failure and cardiomyopathy of
obesity [16]. Weight reduction has a significant impact
in the cardiovascular outcomes of patients with diabetes;
this was proved in many studies that addressed the im-
pact of surgically induced weight reduction on cardio-
vascular outcomes [17, 18], and more recently by Paul
et al. who have shown that cardiovascular outcomes has
significantly improved in patients receiving exenatide or
exenatide plus insulin compared to those receiving insu-
lin only [19].
Table 1 Base line characteristics of participants
Mean ± SD Range
Males = 106 (29 %)
Females = 259 (71 %)
Age 50.4 ± 10 19–65
Weight 96.01 ± 19.2 60–165
HbA1c 8.3 ± 1.7 6–14
Total cholesterol 165.2 ± 40 77–335
Triglycerides 142.3 + 68 36–468
ALT 29 ± 18 4–117
AST 25.1 ± 20 7–315
Creatinine 0.77 ± 0.19 0.4–1.2
Systolic BP 131.6 ± 17 94–200
Diastolic BP 74.4 ± 10 43–110
Baseline medications %









Thyroid disorder 10 %
Fig. 3 Changes in HBA1C in among the studied cases
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tions in total cholesterol and triglycerides in Arab popu-
lation, total cholesterol has dropped from 165.2 ±
40 mg/dl at baseline to 153.6 ± 35 mg/dl (p < 0.001) at
6 months. Triglycerides have changed from 142.3 ±
68 mg/dl at baseline to 131.4 ± 61 mg/dl (p < 0.001) at
6 months. This finding is in keeping with previously
published data that showed significant improvements in
total cholesterol, and triglycerides compared with active
comparators. The reduction in total cholesterol was
5.01 mg/dl from base line after liraglutide treatment,
compared to a 1.93 mg/dl reduction for exenatide [20].Fig. 2 Changes in the body weight in kg among the studied casesIn a study in Japanese patients long-term use of liraglu-
tide for 2 years found to maintain the reduction in body
weight and glycemic control, and also improved lipid
profile and liver enzymes [21].
Treatment with liraglutide was associated with signifi-
cant reduction in systolic blood pressure from baseline
achieved at 26 weeks were 2.59 mmHg (p = 0.008) and
2.49 mmHg (p = 0.003) [22]. In a meta-analysis by Wang
B et al.; the use of liraglutide has resulted in significant
reductions in systolic and diastolic blood pressures when
compared to a placebo or glimepiride. In the 1.2 mg-treated
group, liraglutide treatment reduced SBP compared with
placebo and glimepiride treatment, with mean differences
of −5.60 and −2.38 mmHg, and 95 % CIs of −5.84 to −5.36,
p < 0.00001 and −4.75 to −0.01, p = 0.05, respectively. In the
1.8-mg-treated group, liraglutide also reduced SBP com-
pared with placebo and glimepiride treatment with mean
differences of −4.49 and −2.62 mmHg, and a 95 % CI ofFig. 4 Changes in Total cholesterol and Triglycerides before and
after therapy
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0.00001, respectively [23]. In our cohort there were no
significant reductions in systolic blood pressure, but we
noticed a significant reduction in diastolic blood pressure
on therapy from a mean of 74.4 ± 10 to 72 ± 9 (mmHg) at
6 months this was highly significant with p < 0.001. This
difference could not be explained with the available data.
Further specific study might be required to confirm and
explain, or disprove this finding.
Type2 diabetes often results in renal impairment that
might interfere with the choice of medications used.
Although liraglutide has a slightly wider evidence base
than for exenatide or lixisenatide, there is no enough
evidence to support its use in severe renal impairment
[24]. Patients in our cohort were having normal renal
function; those with stage III renal disease and beyond
were excluded from the study. Liraglutide neither resulted
in improvement or deterioration in kidney function.
Limitations and strengths of the study
This is an observational study conducted to specifically
assess the efficacy of liraglutide therapy in the Arab
population in combination with other anti-diabetic
agents. It is important to note that this is the only study
thus far to report on the use of liraglutide in the Arab
population and is a reflection of real-life clinical practice
in this region. The sample size was calculated to give
95 % power to the study and was found to be 380. We
have enrolled 463 but because of different reasons in-
cluding side effects or loss to follow up, the final number
was 363. Our study was not designed to look at safety
and tolerability of liraglutide, which would have added a
lot of value to the study.
Conclusion
This is the first trial ever conducted to specifically look at
the efficacy of liraglutide in Arab population; and in accord-
ance with studies done in Caucasians, liraglutide therapy as
an add-on to other anti-diabetic agents has proved very ef-
fective in reducing weight and HbA1c in Arab population
with type2 diabetes; these beneficial effects were positive
even after correction for age, sex, medications and co-
morbidities. There was also a significant improvement in
other metabolic parameters including total cholesterol and
triglycerides as well as diastolic blood pressure and liver
enzymes.
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